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Chronic wounds represent a significant health problem worldwide. There is a need for advanced- 
and cost-efficient wound healing products able to increase patient comfort and reduce the healing 
time. The aim of this study was to develop a sprayable hydrogel dressing with beta-glucan (βG) 
as the active ingredient, targeting future application in the treatment of both chronic and burn 
wounds. The βG was chosen as an active ingredient because of its promising wound healing 
capabilities, whereas Carbopol 971P NF (Carbopol) was chosen as the thickening agent in the 
formulation due to several attractive characteristics such as its low viscosity, low toxicity, high 
transparency and good ion tolerance. Four different hydrogel formulations were prepared with 
varying Carbopol concentrations. The higher Carbopol concentration, 0.5 % (w/w), was used to 
prepare three formulations comprising the HighCP:NoβG, HighCP:LowβG and the 
HighCP:MediumβG formulation, respectively. Lower Carbopol concentration, 0.25 % (w/w), 
was used to prepare the LowCP:HighβG formulation. The content of βG varied from 0.25 % in 
the HighCP:LowβG, 0.5 % in the HighCP:MediumβG and 1.0 % (w/w) in the LowCP:HighβG 
formulation, respectively. The first part of the study focused on the rheological characterization 
of the hydrogels and the fluid affinity testing. All formulations were confirmed to be stable gels; 
the βG was shown to augment the gel strength by increasing the yield strength of the gel in a 
dose dependent manner. The stability of the formulations containing either Carbopol alone or in 
a combination with βG did not deteriorate over 26 weeks, and the fluid donation and absorption 
study indicated a fluid donation profile, which favors healing of dry wounds. The in vivo efficacy 
of the formulations, evaluated in the modified diabetic male mice (db/db mice), showed that 
Carbopol alone was unable to induce improved healing and caused adverse reactions in some 
wounds. The inclusion of βG increased the epithelialization and wound contraction in the db/db 
mice when given at high βG:Carbopol ratio. The positive effect of βG was, however, not 
sufficient to counteract the adverse effect of Carbopol, thus a more suitable thickening agent 
should be investigated for further development of a sprayable wound care product. 
 
 




Delayed and incomplete wound healing represents a significant health problem worldwide in an 
increasingly elderly population suffering from medical conditions, such as diabetes, that 
contribute to a higher prevalence of chronical wounds (Han and Ceilley, 2017). The demand for 
suitable dressings to facilitate the biological healing process is therefore huge, despite of a large 
increase in the number of available newer dressings in the last years (Caló and Khutoryanskiy, 
2015). The choice of wound dressing should be evidence-based (King et al., 2017; Frykberg and 
Banks, 2015), and differs according to the underlying pathology, as well as the state of the 
wound (the stage of healing, wound- size, -depth and –location). Thus, there is no dressing that is 
optimal for all wounds (Powers et al., 2013). Ideally, the wound dressings should protect and 
stabilize the wound, providing an optimal moist environment where water is donated to dry 
wounds and excess exudate is absorbed in wet wounds (Caló and Khutoryanskiy, 2015; Boateng 
et al., 2008). The applied dressing should also be biocompatible, non-toxic, gentle to the skin 
upon removal and preferably stimulate the healing process through an active healing ingredient 
(Caló and Khutoryanskiy, 2015).  
An optimal format could be a sprayable wound dressings (Laila et al., 2011; Jones et al., 2006). 
Such a format would have the advantages of multiple-use containers, minimal discomforts 
during application, easy and quick administration onto the wound, provides a big surface contact 
area of the formulation, and easier access to deeper wounds. Moreover, an aerosol system should 
provide a protective gel film on the wound with an optimal wound healing environment, which 
can be covered by a secondary bandage. To form sprayable wound dressing, and assure its 
optimal performance, it is crucial to select the agent with characteristics suitable for spraying 
such as shear thinning properties. This allows for the spray to be pumped through a spray nozzle, 
but maintaining a firm gel layer on the skin or in the wound. One group of gel-forming vehicle 
that has favorable characteristics for use in spray delivery is carbomers. 
Carbomers are a commercially available group of synthetic polymers made from acrylic acids, 
which are crosslinked allyl sucrose or allyl ethers of pentaerythritol. These types of polymers are 
well-known pharmaceutical ingredients in many oral, mucosal and ophthalmic drug 
formulations, as well as in skin products (Lubrizol, 2017). Due to their synthetic origin, the 
polymers are well characterized and the risk of containing contaminants is reduced as compared 
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to polymers isolated from natural origin. Carbopol 971P NF (Carbopol) was chosen as the 
thickening agent, due to several attractive features such as: low viscosity compared to other 
carbomers, low toxicity, high transparency and relatively good ion tolerance (Lubrizol, 2017). 
Considering the shear thinning/pseudoplastic properties of Carbopol, and the physical limitation 
of spray actuators as the delivery device for the hydrogel, the 971P NF was considered to be the 
optimal choice. 
 
Figure 1. Beta-1,3 glucan with 1,6 –branching sidechain of glucose monomers. 
 
An active wound healing ingredient is beta-glucans (Zykova et al., 2014) which forms a 
heterogeneous group of polysaccharides build from β-glucose monomers (Figure 1), where the 
primary structure, molecular weight, branching and polymer charge influence the biological 
activity and solubility of the β-1,3-glucans (Soltanian et al., 2009). Beta-glucans are currently 
used in a number of applications ranging from skin care, medicine, and as food supplements due 
to their immunological (Stier et al., 2014; Novak and Vetvicka, 2008) and anti-inflammatory 
effects (Du et al., 2015).  In this study, we have used a soluble 2.5 % (w/v) beta-glucan (βG), 
containing β-1,3/1,6 glucan extraction and purification from the cell walls of Baker’s yeast 
(Saccharomyces cerevisiae). βG is reported to be a potent inducer of innate immune mechanisms 
both in animal models as well as in human cell cultures (Engstad et al., 2002; Engstad and 
Robertsen, 1994). Regarding  topical application of beta-glucans, various skin diseases have 
been suggested to potentially benefit from the multiple actions of these compounds (i.e. anti-
oxidative, anti-inflammatory, regeneration effect, immunomodulation, radio-protective, 
moisturizing) (Jesenak et al., 2015), and it topical application in dermatology is increasing 
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(Jesenak et al., 2015). Mechanistically, beta-glucan is recognized by innate immune receptors as 
a Pathogen-Associated Molecular Pattern (PAMP). Recognition of PAMPs primes the innate 
immune system, and subsequently the adaptive immune system, preparing it to fight off 
infections. Macrophages, dendritic cells and neutrophils recognize beta-glucan when the 
molecule binds to Dectine-1 receptor, which triggers phagocytosis, respiratory burst and 
inflammatory response (Ma and Underhill, 2013). In wounds, 1,3-linked beta-glucan have been 
shown to enhance migration and proliferation of keratinocytes, which is vital for wound closure 
in humans, thereby accelerating the wound healing (van den Berg et al., 2014). 
In the present work, we attempt to develop a sprayable hydrogel wound dressing, with βG as an 
active ingredient, Carbopol 971P NF as a gel vehicle and glycerol as a stabilizing agent.  
Finally, four different hydrogel formulations were tested in the diabetic mice wound model. The 
wound healing effect was compared to water and a growth factor cocktail as negative and 
positive control, respectively. 
 
2. Materials and methods 
2.1. Materials 
Carbopol® 971P NF (Carbopol) was a gift from The Lubrizol Corporation (Ohio, USA). Milli-Q 
water was produced using Q-Pod® by Merck Millippore (Billerica, MA, USA). The 1,2,3-
propanetriol glycerol was purchased from VWR (Fontenay sous Bois, France). Soluble beta-
1,3/1,6-glucan (βG; 2.5 % w/w) was a gift from Biotec BetaGlucans AS (Tromsø, Norway). 
Sodium hydroxide was purchased from Merck KGaA (Darmstadt, Germany). Gelatin from 
porcine skin and hydroxypropyl methylcellulose (HPMC) were acquired from Sigma-Aldrich 
(Taufkirchen, Germany). Acto™ Agar was purchased from BD (Le Pont de Claix, France). 
IsoFlo® was from Zoetis (London, UK), and Vetergesic® from Alstoe Animal Health (Espoo, 
Finland). Platelet-derived growth factor-BB and Transforming Growth Factor-alpha was 





2.2 Preparation of Carbopol hydrogels  
Four different sprayable hydrogel formulations were prepared; three of those formulations 
contained various concentrations of Carbopol, βG and glycerol, whereas one formulation 
contained no βG (Table 1). The polymer (Carbopol and βG) concentrations applied were selected 
to assure that hydrogels were sprayable: the sprayable polymer concentrations are presented in 
Table S1 (in Supplement S1) 
The hydrogel formulations were prepared by wetting the Carbopol polymer with glycerol prior to 
adding water. The Carbopol-glycerol-water mixture was left to swell overnight. The following 
day, βG was heated to 50 °C before mixing it at low shear with the concentrations listed in Table 
1. Finally, pH was adjusted to 5.0 using 1M NaOH, and all formulations were autoclaved at 121 
˚C for 20 minutes.  
 
Table 1. Hydrogel formulations investigated  
Formulation name 
Carbopol content  
(%, w/w) 
βG content  
(%, w/w) 
Glycerol content  
(%, w/w) 
HighCP:NoβG  0.50 - 10 
HighCP:LowβG 0.50 0.25 10 
HighCP:MediumβG 0.50 0.50 10 
LowCP:HighβG 0.25 1.00 10 
 
 
2.3. Rheological characterization  
The rheological characterizations were performed using a Discovery HR-2 Hybrid Rheometer 
(TA Instruments, New Castle, DE, USA) equipped with 40 mm plate geometry. The plate was 
compressed to a gap of 1050 µm against the platform, excess gel removed and the plate 
geometry lowered to 1000 µm. Two measurement protocols were carried out; namely the 
oscillation time sweep protocol and amplitude sweep protocol, measuring the storage modulus 
(G’) and the loss modulus (G’’) of the unbroken gel strength, and the yield stress, respectively. 
All samples were loaded and soaked for 120 sec to provide a stable test temperature of 25 °C 
during measurements. The oscillation time sweep protocol was carried out with oscillation 
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displacement of 1.0e-3 rad/1.0 Hz for 60 sec. After the oscillation time sweep protocol, the gel 
was left to rest for 30 sec before performing the amplitude sweep protocol. The amplitude sweep 
protocol was performed at 1.0 Hz with the torque range from 100 to 10 000 µN∙m with an 
increment of 100 µN∙m. Results were processed by the Trios software v. 3.2.0.3877 (TA 
Instruments, New Castle, DE, USA) to obtain the different hydrogel`s phase angle and yield 
point using the oscillation time sweep and the amplitude sweep protocol, respectively. 
To characterize the formulations considering the skin temperature the oscillation sweep protocol 
was performed both at 32 °C and 25 °C to determine the relative difference in yield point. 
 
2.4. Viscosity measurements  
Viscosity was measured using a DV-II+ Pro Viscometer equipped with Rheocalc V3.2 by 
Brookfield Engineering Labs (Lorch, Germany). The test formulations were placed in the small 
sample adaptor with a flow jacket for temperature control, and left to soak for 15 minutes at 25 
°C. Samples were tested with either the SC4-31 or SC4-25 spindle, depending on the sample 
viscosity. Higher viscosity samples were tested with the SC4-25 spindle, which requires 16 ml of 
sample, and lower viscosity samples were tested on the SC4-31 spindle requiring 9 ml of sample.  
The IPC (Institute for Interconnecting and Packaging Electronic Circuits) paste model was used 
to determine the 10 rpm viscosity (Equation 1) (Brar et al., 2007).  
 
Equation 1. 
η = kR  
η = Viscosity (cP) 
k = Consistency multiplier 
R = Rotational speed 





2.5. Fluid affinity  
The hydrogel’s water donation and water absorption were measured according to the EU 
standard EN 13726-1:2002 (Standard, 2002). This test emulates dry and exuding wounds by 
using gelatin (35 % w/w) and agar (2 % w/w), respectively, made in “Solution A” (142 mmol 
Na2+, 2.5 mmol Ca2+), that is emulating ion concentration of the blood. The experiment was 
carried out in the pre-prepared 60 ml syringes, purchased from B. Braun Melsungen (Hessen, 
Germany), with their plunger drawn to the 30 ml mark and the tip removed. The agar was heated 
to 121 ± 1 °C for 20 minutes, and subsequently cooled to 60 ± 5 °C before it was filled into the 
pre-prepared syringes. The gelatin was heated to 60 ± 1 °C for 14 ± 1 hours before being filled 
into the pre-prepared syringes. Ten g of either gelatin or agar was filled into each syringe. All 
agar and gelatin syringes were covered with Parafilm® to prevent condensation, and allowed to 
settle at 25 ± 2 °C for three hours. After three hours the Parafilm® was removed, and syringes 
with the content weighed. The hydrogel formulations (10 ± 0.1 g) were then filled into syringes, 
weighed, and covered with Parafilm®. After incubating for 48 hours at 25 ± 2 °C, the Parafilm® 
was removed and the syringes were weighed. Upon the removal of hydrogel, the syringe, with 
either agar or gelatin, was weighed. The test was performed in quintuplicates, and outliers were 
removed using Grubbs test based on the percentage weight change (Grubbs, 1969). 
 
2.6. In vivo wound healing experiments in diabetic mice 
2.6.1. Experimental animals 
The in vivo experimentation was based on the protocol described elsewhere (Hardwicke et al., 
2011). Diabetic mice (BKS.Cg-m Dock7m +/+ Leprdb /J), all male, were purchased from 
Jackson Labs (Bar Harbour, ME, USA), and brought into the animal facilities when 
approximately 9-10 weeks old. The mice were allowed to acclimate for one week prior to the 
start of the study, where the 60 mice included in the study, were randomly divided into six 
experimental groups (10 mice per group) receiving four different treatment formulations (as 
described in Table 1).  , with addition of two control groups. Animals were maintained according 
to the Home Office Regulations UK and the specific requirements of diabetic animals (Home 
Office, 2014). As positive control, a formulation containing 10 µg/dose platelet-derived growth 
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factor and 1 µg/dose transforming growth factor alpha dissolved in 0.5 % (w/v) HPMC was 
applied. Negative control was water. For all tested formulations, including the negative control, a 
volume of 50 μl was administered. The treatment was scheduled to be applied on day 0, 2, 4, 6 
and 8 for the test formulations and negative control, and the positive control treatment scheduled 
on day 0, 1, 2, 3, 4, 5 and 6. The experimental setup is described in more detail in the 
Supplement, Table S2.  
 
2.6.2. Wound induction  
Wound induction took place on a day 0. All mice were anaesthetized using isoflurane and air; 4 
% isoflurane and 96 % (v/v) air for the induction of anesthesia and 2 % isoflurane 98 % (v/v) air 
for maintenance. The skin on their left dorsal flank was shaved and cleansed. A single 
standardized full-thickness wound (10 mm x 10 mm) was created approximately 10 mm from the 
spine. Wound was photographed with an identification plate and calibration rule. The wounds 
were covered with Bioclusive® film dressing, purchased from Systagenix Wound Management 
(Gargrave, UK) and the treatments were applied by an injection through the BioclusiveTM film 
using a 27-gauge needle. All mice were dosed with 75 µg/kg Vetergesic® post-surgery – dose 
volume 100 µl. Dosing was repeated every 12 hours when necessary. 
 
2.6.3. Wound closure assessment 
Image Pro Plus image analysis software (version 4.1.0.0, Media Cybernetics, Rockville, MD, 
USA) was used to calculate the wound closure from scaled wound images taken at each 
assessment point (day 0, 4, 8, 12, 16, 20 and 24). Three different assessments were made from 
the images: 
 (1). Open wound area: Percentage of wound area remaining with time i.e. the open area at a 
given time point relative to the area of the same wound at day 0. 
ℎ      0 −       =   
 
(2) Wound contraction: The difference between the contracted wound area at a given time point 
(solid black line in Figure 2 left panel) and the original wound area (solid black line in Figure 2 
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left panel, red line in Figure 2 right panel), as a percentage of the original wound area (solid 
black line in Figure 2 left panel, red line in Figure 2 right panel). 
ℎ      0 –      =   
 
(3)  Re-epithelialization: i.e. the contracted wound area at a given time (solid black line Figure 2 
right panel) minus the open wound area at that given time (dotted black line Figure 2 left panel, 
red line in 2 right panel) 
    − ℎ       
= – ℎ  
 
All wounds were visually assessed on a daily basis until day 8 – and subsequently every second 
day until day 24 to determine their healing status. Each wound was scored as to whether they 
displayed a neo-dermal tissue generation activity (healing process) or not. Each wound was 
assessed by two independent observers and wounds displaying healing was compared between 




Figure 2. Images with the wound closure terminology applied in the experiments. 
 
2.7. Statistical analysis 
Grubbs test was used to remove outliers in the evaluation of the donation and absorption of 
fluids, and a two tailed t-test was used to determine the difference between time points within the 
groups. P values of < 0.05 were considered as indicative of significant difference between the 
control and treatment group. 
In the animal study determining the remaining wound area, wound contraction and re-
epithelization, the 2 sample non-parametric statistical test Mann-Whitney U-test was used to test 
for statistically significant differences between groups. P values of < 0.05 were considered as 
indicative of significant difference between the control and treatment group.  
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 3. Results and Discussion 
3.1. Rheological characterization of the formulations 
All the formulations were confirmed to be gels, as the storage modulus (G’) was higher than the 
loss modulus (G’’) at 25 °C, represented by a phase angle below 45° during the time sweep 
measurements (Figure 3A). These results also indicate that the inclusion of βG increases the 
hydrogels firmness at rest more than Carbopol.  
The increased amount of βG augmented the gel strength by increasing the yield strength of the 
gel in a dose dependent manner. This stabilizing effect of βG was more pronounced at 25 °C 
than at 32 °C, as the yield point was higher at 25 °C than at 32 °C (Table 2). The results indicate 
that βG increases the strength of the gels, and that this effect was more pronounced at 25 °C, as 
the ratio of yield stress (25 /32 °C) was increasing with an increasing βG content.  
The results from the oscillation sweep measurements (Table 2) showed that 0.5 % (w/w) 
Carbopol gel had a yield point of 21.6 Pa, whereas 2.5 % (w/v) βG had a yield point of 21.0 Pa at 
25 °C. Thus the relative strength of Carbopol was higher than that of βG. 
The HighCP:LowβG formulation, containing 0.5 % Carbopol and 0.25 % βG had a yield point of 
55.0 Pa. It seems that Carbopol and βG have a synergic effect rather than an additive effect on 
the yield point. Carbopol is known as a good stabilizer for a topical formulations (Kim et al., 
2003; Kumbhar et al., 2013). Out results (Table 2) shows that gelling properties of Carbopol is 
more resistant to the higher temperature than βG, as the ratio yield stress (25 /32 °C) was 
increasing with increasing βG content, and varied from 190.3 % to 103.9 % for the 2.5 % (w/v) 








Table 2. The effect of temperature and formulation on the yield point (Pa) using oscillation 
sweep (n=3) 
Temperature 
































Ratio yield point  
((25/32 °C) *100%) 
190.3 % 103.9 % 115.0 % 122.1 % 127.1 % 
 
1) 2.5 % (w/v) Soluble beta-1,3/1,6-glucan (βG). 2)0.5 % (w/w) Carbopol 971P (CP). 3) 0.5 % 
(w/w) CP/0.25 % (w/w) βG. 4) 0.5 % (w/w) CP/0.5 % (w/w) βG. 5) 0.25 % (w/w) CP/1.0 % 
(w/w) βG. 
 
3.2. Stability of the formulations 
The stability of the hydrogels was investigated at 25 °C, measuring the oscillating phase angle 
(Figure 3A) and the yield stress (Figure 3B) at 5 different time points between one and 26 weeks 
post-production, using the oscillation time sweep- and amplitude sweep protocol, respectively. 
Only small variations at different time points within each group were detected; the variation in 
the yield point for the same formulation was less than 10 Pa for all formulations except the 
values for the first week (Figure 3B). The increase in the yield point from the first week after the 
production to the second can be contributed to the delayed onset of 3D gel-network forming by 
polymer aggregation (Ingebrigtsen et al., 2016). Since this difference was not seen in the 
formulation containing only Carbopol, glycerol and water, the effect is most likely due to the 
aggregated nature of the βG molecule as a result of the degree of polymerization and branch 
distribution (Qin et al., 2013).  
As described in Table 1, three of the formulations, namely HighCP:NoβG, HighCP:LowβG and 
HighCP:MediumβG, had the same Carbopol content  (0.5 % (w/w)), whereas the βG content was 
0.0 % (w/w), 0.25 % (w/w) and 0.5 % (w/w), respectively. For the HighβG formulation the 
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amount of Carbopol was 0.25 % (w/w) and the amount of βG was 1.0 % (w/w).  Thus, the yield 
point increased with increasing βG content (Figure 3B); the strength of the gel was higher when 
more βG was included in the formulation. Similarly to the increasing strength corresponding to 
the higher content of βG in the gel, the gel elasticity was also improved in the time sweep 
protocol with the increasing βG content (Figure 3A). 
 
 
Figure 3. The 26-weeks rheological stability of the four hydrogel formulations A) Oscillation 
time sweep stability testing (n=3). B) The amplitude sweep stability testing (n=3). The asterisks 
in week 2 and 26 denotes statistical difference between week 1 and 2, and 2 and 26, respectively 
with p<0.05 (n=3). All formulations contained 10 % (w/w) glycerol, and varying concentrations 
of Carbopol 971P (CP) and Soluble beta-1,3/1,6-glucan (βG): LowCP:HighβG: 0.25 % (w/w) 
CP/1.0 % (w/w) βG. HighCP:MediumβG: 0.5 % (w/w) CP/0.5 % (w/w) βG. HighCP:LowβG: 
0.5 % (w/w) CP/0.25 % (w/w) βG. HighCP:NoβG: 0.5 % (w/w) CP.  
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3.3. Viscosity measurements  
The viscosity of the different formulations applied in the in vivo wound healing study, including  
the positive control (0.5 % w/w) HPMC without growth factor, was measured at 25 °C, and the 
viscosity at 10 rpm (Figure 4) was calculated from the measurements using the IPC Paste model 
(Sharma et al., 2014). The viscosity of the positive control was 22±0.1 cP and the viscosity of the 
negative control (water) is known to be 0.89 cP at 25 °C (Crittenden et al., 2012). The viscosity 
increased in a dose dependent manner with regards to the total polymer content (Carbopol and 
βG) in the formulation. 
 
 
Figure 4. Viscosity of four hydrogel formulations and the positive control in the mice study. 
Viscosity at 10 rpm were calculated using the IPC paste model (n=3). The polymer composition 
of the formulations in MilliQ-water: Positive control: 0.5 % (w/w) hydroxypropyl 
methylcellulose (HPMC). All formulations, except the HPMC formulation, contained 10 % 
(w/w) glycerol, and varying concentrations of Carbopol 971P (CP) and Soluble beta-1,3/1,6-
glucan (βG): LowCP:HighβG: 0.25 % (w/w) CP/1.0 % (w/w) βG. HighCP:MediumβG: 0.5 % 
(w/w) CP/0.5 % (w/w) βG. HighCP:LowβG: 0.5 % (w/w) CP/0.25 % (w/w) βG. 





3.4. Fluid affinity of the hydrogel formulations 
Amorphous hydrogels might encourage wound healing through several mechanisms; supplying 
moisture to dry wounds, promoting rehydration of non-viable tissue, functioning as debriding 
agents, and by providing optimal moist condition for the cell types involved in wound closure 
(Powers et al., 2016; Lay-Flurrie, 2004). Supplying the wound with enough moisture accelerates 
the healing; however providing too much moisture can have negative effect on the tissue, as 
exemplified by maceration of the wound edges (i.e. erosion of the peri-wound tissue) (Powers et 
al., 2016; Schultz et al., 2003). The ability of our formulations to donate and absorb water were 
simulated using gelatin and agar, a water- absorbent and acceptor, respectively, according to the 
standard “EN 13726-1:2002 Test methods for primary wound dressings- Part 1: aspects of 
absorbency” (Standard, 2002). Results are shown in Figure 5. All Carbopol formulations 
exhibited a higher donation than absorbance of liquids. These results might indicate a higher 
stability with increasing content of βG, as the LowCP:HighβG formulation is the only 
formulation that shows no statistical difference in both absorption and donation characteristics 
between the two measurements made after one and nine weeks storage of the gels, respectively. 
However, such a difference in stability was not confirmed by the rheological behavior of the gels 
investigated over 26 weeks (Figure 3). Use of amorphous hydrogel, such as the Carbopol-
containing formulations tested in this study, is recommended for treatment of the shallow and 
deep open wounds e.g. pressure sores, leg ulcers, surgical and malignant wounds, partial 




Figure 5. Absorbency and donation characteristics of the five hydrogel formulations after one 
and nine weeks of storage. Asterisk denotes statistical differences (p<0.05) between week one 
and week nine, using a two tailed t-test (n=5). All formulations contained 10 % (w/w) glycerol, 
and varying concentrations of Carbopol 971P (CP) and Soluble beta-1,3/1,6-glucan (βG): 
LowCP:HighβG: 0.25 % (w/w) CP/1.0 % (w/w) βG. HighCP:MediumβG: 0.5 % (w/w) CP/0.5 
% (w/w) βG. HighCP:LowβG: 0.5 % (w/w) CP/0.25 % (w/w) βG. HighCP:NoβG: 0.5 % (w/w) 
CP.  
 
3.5. In vivo wound healing in mice 
3.5.1 Wound model 
To predict the efficacy of the hydrogel formulations in human wound healing, and the immune-
modulating effect of the hydrogel and its active component, the formulations were tested in 
diabetic mice. The mechanisms of wound healing in the rodent models differ from humans in 
that they heal by both contraction of the wound margins and re-epithelialization (Abdullahi et al., 
2014). As such, the usefulness of mice models for wound healing have been questioned as the 
mechanisms for wound closure in human mainly depend on re-epithelialization. However, it has 
recently been demonstrated that the wound healing in db/db mice depend equally on both 
contraction and re-epithelialization (Chen et al., 2015), thus making it a useful model for wound 
healing studies still. 
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Previously, commercial hydrogel formulations containing the same βG as in this study, have 
been tested in the db/db mouse model (Skjæveland and Engstad, 2013). The study showed a 
statistically significant (p<0.05) better angiogenesis and wound contraction with βG and carrier 
(carboxymethyl cellulose) as compared to treatment with the carrier alone or water control (pers. 
comm.). However, the concentration used in the study was 2 % (w/w), whereas in this study we 
tested a maximum βG concentration of 1 % (w/w) only. The design of the study did not allow the 
end product as a spray delivery device to be tested, since the gel was injected under a 
polyurethane dressing. Thus, it should be noted that the occlusive bandages alone is known to 
accelerate the wound healing by maintaining a moist environment in the wound, as compared to 
an open wound without any dressing (Hinman and Maibach, 1963; Winter, 1962) . 
 
3.5.2. Wound closure, contraction and re-epithelization  
Wound closure (expressed as % of open wound area relative to the wound area measured at 
wounding) results from the combined effects of wound contraction (the inward movement of 
marginal tissue) and re-epithelialization (wound resurfacing by the inward migration of epithelial 
cells) (Wong et al., 2011). Wound closure over time was a consequence of both processes. Since 
the extent of contraction can differ between the treatment groups, the level of contraction and its 
impact on the re-epithelialization, particularly at the later time points, was considered. Positive 
control treatment was found to significantly (p<0.05) accelerate the wound closure process 
compared to the water treatment (Figure 6). No peri-wound damage was recorded with neither 
water control treatment nor with the positive controls, and no significant difference in the level 
of weight loss of the animals were observed (p<0.05). As shown in Figure 6, the four 
formulations HighCP:LowβG, HighCP:MediumβG, LowCP:HighβG and HighCP:NoβG, had no 
promotional effect on the wound closure relative to water treatment. For some formulations even 
deleterious effects were observed. The last application of the test formulations on day 8 was 
withheld due to adverse reaction (Table S2, in supplements). Also, 7 out of the 60 animals in 
treatment were euthanized before the end of the study, do to animal welfare reasons, i.e. the lack 
of wound healing (for more details: Supplement S4, Table S3). The adverse effects observed 
included oedema, ischemia, apparent loss of tissue viability and erosion of the peri-wound skin 
(maceration); these side effects became evident within the first 4 days of treatment. Photographs 
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representing the adverse reactions (such as edema, ischemia etc.) and the wound healing 
progression observed, are provided in the supplementary information, Figure S1 to S3. 
Comparing the four Carbopol formulations, the treatment with the LowCP:HighβG formulation 
resulted in the highest re-epithelialization from day 12 onwards (Figure 8). Treatment with 
LowCP:HighβG resulted in significantly higher levels of wound re-epithelialization relative to 
HighCP:MediumβG on days 8 and 20 (p<0.05), relative to HighCP:LowβG on days 12 to 24 
(p<0.05) and relative to Carbopol at all time-points (p<0.05). These enhanced contractions 
indicate an improvement in the granulation tissue function; which may in turn be explained by an 
increase in the amount of granulation tissue formed, an increase in the speed at which it is 
formed, or increased contractile capacity of the tissue (Greenhalgh et al., 1990). With the 
exception of LowCP:HighβG, the experimental formulations had little or no positive impact on 
the wound contraction relative to water-treatment (Figure 7). However, LowCP:HighβG 
treatment increased contraction significantly (p<0.05) compared to water treatment on days 20 
and 24. 
Re-epithelialization peaked around day 16 in the positive control-treated group; after which time 
it decreased (Figure 8). The reduction in re-epithelialization (normally after day 16) is an 
artefact. This is due to the shrinkage of the underlying neo-dermal tissue, due to wound 
contraction, which leads to compaction of the neo-epithelium on the wound surface (Ehrlich and 
Hunt, 2012). The positive control group displayed the greatest peak in re-epithelialization with 
significantly higher levels (p<0.05) than all other treatments. Control wounds treated with water, 
re-epithelialized slowly, but progressively, until day 24. The formulations containing Carbopol 
re-epithelized slower than water, however, the inclusion of βG increased the re-epithelialization 
as compared to HighCP:NoβG (Figure 8). The low rate of epithelialization seen in Figure 8, in 
combination with the remaining open wound (Figure 6) suggest that the wound healing in the 
groups treated with the Carbopol containing formulation are, to a larger extent, dependent on the 
contraction of the panniculus carnosus rather than regeneration of  tissue (Abdullahi et al., 
2014). However, the mechanism behind adverse reactions observed for Carbopol hydrogels 
remains to be explored and explained. 
Of the four test Carbopol formulations, the formulation with the highest βG concentration 
(LowCP:HighβG) did not give side effects such as ischemia and maceration, and demonstrated a 
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small, non-significant trend toward increased wound closure relative to the water (and the other 
spray formulations) from day 8 onwards (Figure 6).  
 
 
Figure 6. The relative wound closure after different treatments (± sem) (n=10). Composition of 
the formulations in MilliQ-water: Positive control: 10 µg/dose platelet-derived growth factor 
and 1µg/dose transforming growth factor alpha in 0.5 % (w/v) hydroxypropyl methylcellulose 
0.5 % (w/w). All formulations, except control formulations, contained 10 % (w/w) glycerol, and 
varying concentrations of Carbopol 971P (CP) and Soluble beta-1,3/1,6-glucan (βG): 
LowCP:HighβG: 0.25 % (w/w) CP/1.0 % (w/w) βG. HighCP:MediumβG: 0.5 % (w/w) CP/0.5 





Figure 7. Wound contraction with time; % change from mean area of original wound closure by 
contraction (% ± sem) (n=10). Positive control: 10 µg/dose platelet-derived growth factor and 
1µg/dose transforming growth factor alpha in 0.5 % (w/v) hydroxypropyl methylcellulose 0.5 % 
(w/w). All formulations, except control formulations, contained 10 % (w/w) glycerol, and 
varying concentrations of Carbopol 971P (CP) and Soluble beta-1,3/1,6-glucan (βG): 
LowCP:HighβG: 0.25 % (w/w) CP/1.0 % (w/w) βG. HighCP:MediumβG: 0.5 % (w/w) CP/0.5 





Figure 8. Re-epithelization; change in mean % of original wound closed by re-epithelization 
with time (mean % area ± sem) (n=10). Positive control: 10 µg/dose platelet-derived growth 
factor and 1µg/dose transforming growth factor alpha in 0.5 % (w/v) hydroxypropyl 
methylcellulose 0.5 % (w/w). All other formulations, except control formulations, contained 10 
% (w/w) glycerol, and varying concentrations of Carbopol 971P (CP) and Soluble beta-1,3/1,6-
glucan (βG): LowCP:HighβG: 0.25 % (w/w) CP/1.0 % (w/w) βG. HighCP:MediumβG: 0.5 % 
(w/w) CP/0.5 % (w/w) βG. HighCP:LowβG: 0.5 % (w/w) CP/0.25 % (w/w) βG. 
HighCP:NoβG: 0.5 % (w/w) CP.  
 
4. Conclusions 
The applied thickening/gelling agent Carbopol 971P NF showed good rheological properties 
considering its usage in a sprayable device destined for wound treatment, as it was acting as a 
fluid under higher share stress (spraying) and returning to a gel at lower share stress (e.g. in 
wound). However, our in vivo data in the murine db/db wound model indicate that the Carbopol 
971P NF alone does not accelerate the healing process, but does in fact have deleterious effects. 
Inclusion of the active ingredient, soluble beta-1,3/1,6-glucan (βG), increased the re-
epithelialization and wound contraction in the db/db mice. However, the positive effect of βG 
was not sufficient to counteract the adverse effect of Carbopol 971P NF in wound healing. A 
more suitable thickening agent should therefore be investigated, as well as a higher inclusion of 
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S1. Pilot experiment: Sprayability 
Sprayability of hydrogels with 1% (w/w) βG, 10 % (w/w) glycerol and increasing concentration 
of Carbopol was tested with two COMFORT® airless actuators (Ursatec Verpackung GmbH, 
Germany) with a spray dose of 45 and 140 µl pr dose. The results from these experiments are 
presented in Table S1.  
 
Table S1. Sprayability of hydrogels containing 1% (w/w) βG 10 % (w/w) glycerol and 
increasing concentration of Carbopol. 
Formulation no Carbopol 
concentration (w/w) 
45 µl actuator 140 µl actuator 
1  0.25 % Sprayable Sprayable 
2 0.50 % Sprayable Sprayable 
3 0.75 % Sprayable/jet Sprayable/jet 
4 1.00 % Jet Jet 
5 1.25 % Jet Jet 
6 1.50 % Jet Jet 
 
The actuators provided a mist or spray of small droplets (aerosol) for all the applied 
formulations, with both the 40 and 140 µl actuator, until a Carbopol concentration of 0.75% 
(w/w) was reached. At this concentration, the quality of the spray was reduced, and a jet rather 
than an aerosol of droplets was observed.  There was no noticeable difference between the two 
different actuators.  
Of the selected formulations applied in the final study, the hydrogel with highest viscosity was 
the LowCP: HighβG formulation, containing 0.25% (w/w) Carbopol and 1.0% (w/w) βG and 
10% (w/w) glycerol corresponding to Formulation 1 in Table S1. Viscosity values for all 





S2. Experimental setup for the in vivo wound healing study in mice 
A schematic presentation of the experimental setup for the in vivo studies are given in Table S2. 
Table S2. Experimental setup for the wound healing experiments.  
Group 
no. 
Formulation applied Day of treatment (x) Day of (re-)anaesthetization (A) 
Photography (P) 
0 1 2 3 4 5 6 7 8 12 16 20 24 
1 Positive control x x x x x x x       
2* HighCP:NoβG  x  x  x  x       
3* HighCP:LowβG x  x  x  x       
4* HighCP:MediumβG x  x  x  x       
5* LowCP:HighβG x  x  x  x       
6 Negative control x  x  x  x  x     
1-6 Anesthetic treatment A    A    A A A A  
1-6 Photography  P    P    P P P P P 
*Group 2-5 were planned to be treated (x) also on day 8, but due to adverse effects in some 





S3. Wound healing assessment  
Each of the 6 treatment groups in the in vivo experiment consisted of 10 diabetic mice (BKS.Cg-
m Dock7m +/+ Leprdb /J) with a total of 60 animals. The response to treatment within the group 
varied. An example of intra-group variation can be seen when comparing photographs taken 
during wound healing given in Figure S1 and Figure S2. Bothe the mice in Figure S1 and Figure 
S2 were treated with HighCP:NoβG formulation. The buildup of slough and serious maceration 
and ischemia is visible in in Figure S1, especially during day 20 and 24, whereas moderate 
ischemia, maceration, and no slough buildup can be seen in Figure S2.  In the LowCP:HighβG 
treated group the animals were less prone to maceration, ischemia and slough buildup (Figure 

















S4. Animal euthanized made do to animal welfare reasons  
Seven out of the 60 animals applied in this in vivo wound healing study were euthanized prior to 
the study completion due to welfare issues (Table S3). In 5 of 6 cases, the mouse was euthanized 
because it became evident that the wound would not heal, and the reason for euthanization was 
defined “related to the treatment”. This included secondary wounds appearing due to self-
mutilation or ischemia and maceration, primary wound enlargement with possible infections and 
with wound margins erythematous, ischemic and macerated.  The mouse that had to be 
euthanized in Group no 2 had an abscess in the mouth, and this was not defined “unrelated to 
treatment”.    
Table S3. Number of animals euthanized at given time points (day) in the study   
Group 
no. 
Formulation applied Euthanasia (E) day 
0 1 2 3 4 5 6 8 10 12 16 20 24 
1 Positive control             10E 
2 HighCP:LowβG           1E*  9E 
3 HighCP:MediumβG        1E 1E 1E  1E 6E 
4 LowCP:HighβG             10E 
5 HighCP:NoβG            1E 9E 
6 Negative control            1E* 9E 
*Reason unrelated to treatment 
 
 
